This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Pilot Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Eye Institute (NEI) )
ClinicalTrials.gov Identifier:
NCT00837252
First received: February 4, 2009
Last updated: September 22, 2016
Last verified: September 2016
Results First Received: April 21, 2011  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Retinal Disease
Intervention: Drug: Finasteride

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Finasteride All five study participants (all of whom were diagnosed with chronic CSC) were administered a 5mg oral dose of finasteride daily for three months. After three months, the finasteride was withheld and the participants were observed for another three months.

Participant Flow:   Overall Study
    Finasteride
STARTED   5 
COMPLETED   5 
NOT COMPLETED   0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Finasteride No text entered.

Baseline Measures
   Finasteride 
Overall Participants Analyzed 
[Units: Participants]
 5 
Age 
[Units: Participants]
 
<=18 years   0 
Between 18 and 65 years   5 
>=65 years   0 
Age 
[Units: Years]
Mean (Standard Deviation)
 50  (10.4) 
Gender 
[Units: Participants]
 
Female   0 
Male   5 
Region of Enrollment 
[Units: Participants]
 
United States   5 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Change in Visual Acuity at Month 3 Compared to Baseline.   [ Time Frame: 3 months ]

2.  Secondary:   Change in Visual Acuity at Month 6 Compared to Baseline   [ Time Frame: 6 months ]

3.  Secondary:   Change in Center-Subfield Macular Thickness at Month 3 Compared to Baseline   [ Time Frame: 3 months ]

4.  Secondary:   Change in Center-Subfield Macular Thickness at Month 6 Compared to Baseline   [ Time Frame: 6 months ]

5.  Secondary:   Change in Subretinal Fluid Volume at Month 3 Compared to Baseline   [ Time Frame: 3 Months ]

6.  Secondary:   Change in Subretinal Fluid Volume at Month 6 Compared to Baseline   [ Time Frame: 6 Months ]

7.  Secondary:   Change in Serum Dihydrotestosterone (DHT) Concentration at Month 3 Compared to Baseline   [ Time Frame: 3 Months ]

8.  Secondary:   Change in Serum Dihydrotestosterone (DHT) Concentration at Month 6 Compared to Baseline   [ Time Frame: 6 Months ]

9.  Secondary:   Change in Serum Testosterone Level at Month 3 Compared to Baseline   [ Time Frame: 3 Months ]

10.  Secondary:   Change in Serum Testosterone Level at Month 6 Compared to Baseline   [ Time Frame: 6 Months ]

11.  Secondary:   Change in Urinary Cortisol Level at Month 3 Compared to Baseline   [ Time Frame: 3 Months ]

12.  Secondary:   Change in Urinary Cortisol Level at Month 6 Compared to Baseline   [ Time Frame: 6 Months ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Catherine M. Meyerle, MD
Organization: National Eye Institute
phone: 301-435-7821
e-mail: meyerlec@nei.nih.gov


Publications of Results:
Other Publications:

Responsible Party: National Institutes of Health Clinical Center (CC) ( National Eye Institute (NEI) )
ClinicalTrials.gov Identifier: NCT00837252     History of Changes
Other Study ID Numbers: 090075
09-EI-0075 ( Other Identifier: National Eye Institute IRB )
Study First Received: February 4, 2009
Results First Received: April 21, 2011
Last Updated: September 22, 2016